EXEL Exelixis, Inc.
$58.16
Exelixis, Inc. (EXEL) is expected to report earnings on November 2, 2026, after the market close. The consensus earnings estimate is $0.79 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.9% since its last earnings release on August 5, 2026.
Exelixis Missed Expectations, Lowers Guidance
Wednesday, August 5, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 2
Monday · 4:05 PM ET
Earnings Whisper
-
vs $0.79
(GAAP)
Rev est $653.06M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$55.26
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Exelixis, Inc.
Exelixis Inc is a biotechnology company that develops small molecule therapies for the treatment of cancer.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.